U.S. Stock Movement | Teva Pharmaceutical (TEVA.US) Surges Nearly 13% Pre-Market as Q3 Revenue and Adjusted EPS Beat Expectations

Stock News

Nov 05

On Wednesday, Teva Pharmaceutical (TEVA.US) surged nearly 13% in pre-market trading to $23.10. The company reported Q3 revenue of $4.48 billion, surpassing market expectations of $4.34 billion. Adjusted earnings per share (EPS) came in at $0.78, beating the consensus estimate of $0.68.

For fiscal year 2025, Teva expects full-year revenue in the range of $16.8 billion to $17 billion, compared to FactSet's projection of $16.83 billion. Additionally, the company raised its adjusted EPS guidance for 2025 from $2.50-$2.60 to $2.55-$2.65, while analysts had anticipated $2.58.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1155567528"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1155567528\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1155567528?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 22:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155567528","market":"other","top_or_hot":-1,"title":"U.S. Stock Movement | Teva Pharmaceutical (TEVA.US) Surges Nearly 13% Pre-Market as Q3 Revenue and Adjusted EPS Beat Expectations","media":"Stock News","content":"<p>On Wednesday, Teva Pharmaceutical (TEVA.US) surged nearly 13% in pre-market trading to $23.10. The company reported Q3 revenue of $4.48 billion, surpassing market expectations of $4.34 billion. Adjusted earnings per share (EPS) came in at $0.78, beating the consensus estimate of $0.68.</p>\n<p>For fiscal year 2025, Teva expects full-year revenue in the range of $16.8 billion to $17 billion, compared to FactSet's projection of $16.83 billion. Additionally, the company raised its adjusted EPS guidance for 2025 from $2.50-$2.60 to $2.55-$2.65, while analysts had anticipated $2.58.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. Stock Movement | Teva Pharmaceutical (TEVA.US) Surges Nearly 13% Pre-Market as Q3 Revenue and Adjusted EPS Beat Expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. Stock Movement | Teva Pharmaceutical (TEVA.US) Surges Nearly 13% Pre-Market as Q3 Revenue and Adjusted EPS Beat Expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-05 22:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On Wednesday, Teva Pharmaceutical (TEVA.US) surged nearly 13% in pre-market trading to $23.10. The company reported Q3 revenue of $4.48 billion, surpassing market expectations of $4.34 billion. Adjusted earnings per share (EPS) came in at $0.78, beating the consensus estimate of $0.68.</p>\n<p>For fiscal year 2025, Teva expects full-year revenue in the range of $16.8 billion to $17 billion, compared to FactSet's projection of $16.83 billion. Additionally, the company raised its adjusted EPS guidance for 2025 from $2.50-$2.60 to $2.55-$2.65, while analysts had anticipated $2.58.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"","article_id":"1155567528","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155567528","pubTimestamp":1762351454,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"On Wednesday, Teva Pharmaceutical (TEVA.US) surged nearly 13% in pre-market trading to $23.10. The company reported Q3 revenue of $4.48 billion, surpassing market expectations of $4.34 billion....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4584":"避孕概念","BK4585":"ETF&股票定投概念","BK4557":"大麻股","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","BK4596":"哈里斯概念","BK4559":"巴菲特持仓","BK4007":"制药","TEVA":"梯瓦制药","BK4566":"资本集团"},"translate_title":"美股动向|梯瓦制药(TEVA.US)盘前大涨近13%，Q3营收和调整后EPS均超预期","themeId":"0e10452748c8c56d37b9e4059781f9d7","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":1},"content_text":"On Wednesday, Teva Pharmaceutical (TEVA.US) surged nearly 13% in pre-market trading to $23.10. The company reported Q3 revenue of $4.48 billion, surpassing market expectations of $4.34 billion. Adjusted earnings per share (EPS) came in at $0.78, beating the consensus estimate of $0.68.\nFor fiscal year 2025, Teva expects full-year revenue in the range of $16.8 billion to $17 billion, compared to FactSet's projection of $16.83 billion. Additionally, the company raised its adjusted EPS guidance for 2025 from $2.50-$2.60 to $2.55-$2.65, while analysts had anticipated $2.58.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}